Michael Mobley
Psychiatry · Savannah, GANPI 1386626646
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.5% of the total across 209 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by AbbVie at 26.1% of the total. Reporting peaked in 2021 at $1,113 and has fallen 91.0% since, to $100 in 2025.
Across 209 payments — averaging $15.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$843
- Avanir Pharmaceuticals, Inc.$523
- Teva Pharmaceuticals USA, Inc.$340
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$291
- Johnson & Johnson$280
- Sunovion Pharmaceuticals Inc.$201
- plus $748 from 12 others
Across 457 payments — averaging $6284.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sage Therapeutics, LLC$1.1M
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$910K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$418K
- AbbVie$201K
- E.r. Squibb & Sons, L.L.C.$89K
- Biohaven Pharmaceuticals, Inc.$67K
- plus $115K from 5 others
What the payments were for
- Food & beverage$3,17999%
- Education$471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 60 | $843 |
| Avanir Pharmaceuticals, Inc. | 41 | $523 |
| Teva Pharmaceuticals USA, Inc. | 15 | $340 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 31 | $291 |
| Johnson & Johnson | 14 | $280 |
| Sunovion Pharmaceuticals Inc. | 11 | $201 |
| Otsuka America Pharmaceutical, Inc. | 9 | $166 |
| Alkermes, Inc. | 6 | $122 |
| Biogen | 1 | $100 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $91 |
| Vanda Pharmaceuticals Inc. | 5 | $79 |
| Eisai Inc. | 3 | $47 |
| Neurocrine Biosciences, Inc. | 2 | $37 |
| Alfasigma USA, Inc. | 2 | $34 |
| Ironshore Pharmaceuticals Inc. | 1 | $20 |
| Lundbeck LLC | 1 | $19 |
| Adlon Therapeutics L.p. | 1 | $17 |
| Acadia Pharmaceuticals Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,226 in reported general payments places this provider in the 80th percentile of 900 psychiatry providers in Georgia.
Other psychiatry in Savannah
- Chad BrockSavannah$16K
- Arnold NegrinSavannah$14K
- Richard PettyLoganville$2.9M
- Ann GrooverCalhoun$1.4M
- Todd AntinDecatur$1M
- Michael BanovMarietta$733K
- Ben HunterBrookhaven$499K
- Joel MorganValdosta$337K
- Munjal ShroffSmyrna$316K
- David PurselleAtlanta$307K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.